An interview with Dr Matt SilverCell Therapeutics, Inc. announced today that the U.S. Meals and Drug Administration’s Oncologic Medicines Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for individuals with relapsed or refractory intense non-Hodgkin’s lymphoma . Presently, there are no approved drugs for individuals with relapsed or refractory intense NHL that have received two or more prior therapies. Pixantrone will be the first drug accepted by the FDA for this indication.Albicans species. What we discovered was that the majority of the Candida genital isolates had been in fact vunerable to azole treatments, said Lisboa-Silva, but we found some Candida isolates got itraconazole resistance phenotype. She added that although we missed any association between resistance and some scientific data and outcomes, it is very important to keep to monitor this pattern of susceptibility of Candida because it’s an extremely frequent clinical situation and nowadays the usage of antifungals can be very frequent therefore we have to know what the impact of this practice is inside our clinic.